FDA Clears Sekisui Dx's HbA1c Assay

Jul 30, 2018

NEW YORK (360Dx) – Sekisui Diagnostics said today that the US Food and Drug Administration has cleared the company's Sekure HbA1c assay as an aid in the diagnosis of diabetes mellitus.

It also has been cleared to aid in identifying patients at risk of developing diabetes mellitus and for the monitoring of long-term blood glucose control of patients with the condition.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Main menu